Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies

Background and Objective : Plasma biomarkers for the diagnosis and stratification of Alzheimer’s disease (AD) are intensively sought. However, no plasma markers are well established so far for AD diagnosis. Our group has identified and validated various blood-based proteomic biomarkers relating to A...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in aging neuroscience Vol. 13; p. 712545
Main Authors Shi, Liu, Buckley, Noel J., Bos, Isabelle, Engelborghs, Sebastiaan, Sleegers, Kristel, Frisoni, Giovanni B., Wallin, Anders, Lléo, Alberto, Popp, Julius, Martinez-Lage, Pablo, Legido-Quigley, Cristina, Barkhof, Frederik, Zetterberg, Henrik, Visser, Pieter Jelle, Bertram, Lars, Lovestone, Simon, Nevado-Holgado, Alejo J.
Format Journal Article
LanguageEnglish
Published Lausanne Frontiers Research Foundation 21.07.2021
Frontiers Media S.A
Subjects
Aging
Alzheimer's disease
Alzheimer's disease (AD)
Apolipoproteins
association
Biomarkers
blood
blood biomarkers
clinical-diagnosis
Cognitive ability
Cytotoxicity
Dementia
Dementia disorders
Diagnosis
Fibrinogen
Frontotemporal dementia
Geriatrics & Gerontology
insulin-resistance
Lifestyles
Lymphocytes T
Meta-analysis
national institute
Neurodegenerative diseases
neurofilament light
Neuroscience
Neurosciences
Neurosciences & Neurology
Neurovetenskaper
Pathology
phosphorylated tau 181
Plasma
Proteins
proteomic
α2-Macroglobulin
United States > US
San Francisco California
California
Online AccessGet full text

Cover

Abstract Background and Objective : Plasma biomarkers for the diagnosis and stratification of Alzheimer’s disease (AD) are intensively sought. However, no plasma markers are well established so far for AD diagnosis. Our group has identified and validated various blood-based proteomic biomarkers relating to AD pathology in multiple cohorts. The study aims to conduct a meta-analysis based on our own studies to systematically assess the diagnostic performance of our previously identified blood biomarkers. Methods : To do this, we included seven studies that our group has conducted during the last decade. These studies used either Luminex xMAP or ELISA to measure proteomic biomarkers. As proteins measured in these studies differed, we selected protein based on the criteria that it must be measured in at least four studies. We then examined biomarker performance using random-effect meta-analyses based on the mean difference between biomarker concentrations in AD and controls (CTL), AD and mild cognitive impairment (MCI), MCI, and CTL as well as MCI converted to dementia (MCIc) and non-converted (MCInc) individuals. Results : An overall of 2,879 subjects were retrieved for meta-analysis including 1,053 CTL, 895 MCI, 882 AD, and 49 frontotemporal dementia (FTD) patients. Six proteins were measured in at least four studies and were chosen for meta-analyses for AD diagnosis. Of them, three proteins had significant difference between AD and controls, among which alpha-2-macroglobulin (A2M) and ficolin-2 (FCN2) increased in AD while fibrinogen gamma chain (FGG) decreased in AD compared to CTL. Furthermore, FGG significantly increased in FTD compared to AD. None of the proteins passed the significance between AD and MCI, or MCI and CTL, or MCIc and MCInc, although complement component 4 (CC4) tended to increase in MCIc individuals compared to MCInc. Conclusions : The results suggest that A2M, FCN2, and FGG are promising biomarkers to discriminate AD patients from controls, which are worthy of further validation.
AbstractList Background and Objective: Plasma biomarkers for the diagnosis and stratification of Alzheimer’s disease (AD) are intensively sought. However, no plasma markers are well established so far for AD diagnosis. Our group has identified and validated various blood-based proteomic biomarkers relating to AD pathology in multiple cohorts. The study aims to conduct a meta-analysis based on our own studies to systematically assess the diagnostic performance of our previously identified blood biomarkers.Methods: To do this, we included seven studies that our group has conducted during the last decade. These studies used either Luminex xMAP or ELISA to measure proteomic biomarkers. As proteins measured in these studies differed, we selected protein based on the criteria that it must be measured in at least four studies. We then examined biomarker performance using random-effect meta-analyses based on the mean difference between biomarker concentrations in AD and controls (CTL), AD and mild cognitive impairment (MCI), MCI, and CTL as well as MCI converted to dementia (MCIc) and non-converted (MCInc) individuals.Results: An overall of 2,879 subjects were retrieved for meta-analysis including 1,053 CTL, 895 MCI, 882 AD, and 49 frontotemporal dementia (FTD) patients. Six proteins were measured in at least four studies and were chosen for meta-analyses for AD diagnosis. Of them, three proteins had significant difference between AD and controls, among which alpha-2-macroglobulin (A2M) and ficolin-2 (FCN2) increased in AD while fibrinogen gamma chain (FGG) decreased in AD compared to CTL. Furthermore, FGG significantly increased in FTD compared to AD. None of the proteins passed the significance between AD and MCI, or MCI and CTL, or MCIc and MCInc, although complement component 4 (CC4) tended to increase in MCIc individuals compared to MCInc.Conclusions: The results suggest that A2M, FCN2, and FGG are promising biomarkers to discriminate AD patients from controls, which are worthy of further validation.
Background and Objective : Plasma biomarkers for the diagnosis and stratification of Alzheimer’s disease (AD) are intensively sought. However, no plasma markers are well established so far for AD diagnosis. Our group has identified and validated various blood-based proteomic biomarkers relating to AD pathology in multiple cohorts. The study aims to conduct a meta-analysis based on our own studies to systematically assess the diagnostic performance of our previously identified blood biomarkers. Methods : To do this, we included seven studies that our group has conducted during the last decade. These studies used either Luminex xMAP or ELISA to measure proteomic biomarkers. As proteins measured in these studies differed, we selected protein based on the criteria that it must be measured in at least four studies. We then examined biomarker performance using random-effect meta-analyses based on the mean difference between biomarker concentrations in AD and controls (CTL), AD and mild cognitive impairment (MCI), MCI, and CTL as well as MCI converted to dementia (MCIc) and non-converted (MCInc) individuals. Results : An overall of 2,879 subjects were retrieved for meta-analysis including 1,053 CTL, 895 MCI, 882 AD, and 49 frontotemporal dementia (FTD) patients. Six proteins were measured in at least four studies and were chosen for meta-analyses for AD diagnosis. Of them, three proteins had significant difference between AD and controls, among which alpha-2-macroglobulin (A2M) and ficolin-2 (FCN2) increased in AD while fibrinogen gamma chain (FGG) decreased in AD compared to CTL. Furthermore, FGG significantly increased in FTD compared to AD. None of the proteins passed the significance between AD and MCI, or MCI and CTL, or MCIc and MCInc, although complement component 4 (CC4) tended to increase in MCIc individuals compared to MCInc. Conclusions : The results suggest that A2M, FCN2, and FGG are promising biomarkers to discriminate AD patients from controls, which are worthy of further validation.
Background and Objective: Plasma biomarkers for the diagnosis and stratification of Alzheimer's disease (AD) are intensively sought. However, no plasma markers are well established so far for AD diagnosis. Our group has identified and validated various blood-based proteomic biomarkers relating to AD pathology in multiple cohorts. The study aims to conduct a meta-analysis based on our own studies to systematically assess the diagnostic performance of our previously identified blood biomarkers. Methods: To do this, we included seven studies that our group has conducted during the last decade. These studies used either Luminex xMAP or ELISA to measure proteomic biomarkers. As proteins measured in these studies differed, we selected protein based on the criteria that it must be measured in at least four studies. We then examined biomarker performance using random-effect meta-analyses based on the mean difference between biomarker concentrations in AD and controls (CTL), AD and mild cognitive impairment (MCI), MCI, and CTL as well as MCI converted to dementia (MCIc) and non-converted (MCInc) individuals. Results: An overall of 2,879 subjects were retrieved for meta-analysis including 1,053 CTL, 895 MCI, 882 AD, and 49 frontotemporal dementia (FTD) patients. Six proteins were measured in at least four studies and were chosen for meta-analyses for AD diagnosis. Of them, three proteins had significant difference between AD and controls, among which alpha-2-macroglobulin (A2M) and ficolin-2 (FCN2) increased in AD while fibrinogen gamma chain (FGG) decreased in AD compared to CTL. Furthermore, FGG significantly increased in FTD compared to AD. None of the proteins passed the significance between AD and MCI, or MCI and CTL, or MCIc and MCInc, although complement component 4 (CC4) tended to increase in MCIc individuals compared to MCInc. Conclusions: The results suggest that A2M, FCN2, and FGG are promising biomarkers to discriminate AD patients from controls, which are worthy of further validation.Background and Objective: Plasma biomarkers for the diagnosis and stratification of Alzheimer's disease (AD) are intensively sought. However, no plasma markers are well established so far for AD diagnosis. Our group has identified and validated various blood-based proteomic biomarkers relating to AD pathology in multiple cohorts. The study aims to conduct a meta-analysis based on our own studies to systematically assess the diagnostic performance of our previously identified blood biomarkers. Methods: To do this, we included seven studies that our group has conducted during the last decade. These studies used either Luminex xMAP or ELISA to measure proteomic biomarkers. As proteins measured in these studies differed, we selected protein based on the criteria that it must be measured in at least four studies. We then examined biomarker performance using random-effect meta-analyses based on the mean difference between biomarker concentrations in AD and controls (CTL), AD and mild cognitive impairment (MCI), MCI, and CTL as well as MCI converted to dementia (MCIc) and non-converted (MCInc) individuals. Results: An overall of 2,879 subjects were retrieved for meta-analysis including 1,053 CTL, 895 MCI, 882 AD, and 49 frontotemporal dementia (FTD) patients. Six proteins were measured in at least four studies and were chosen for meta-analyses for AD diagnosis. Of them, three proteins had significant difference between AD and controls, among which alpha-2-macroglobulin (A2M) and ficolin-2 (FCN2) increased in AD while fibrinogen gamma chain (FGG) decreased in AD compared to CTL. Furthermore, FGG significantly increased in FTD compared to AD. None of the proteins passed the significance between AD and MCI, or MCI and CTL, or MCIc and MCInc, although complement component 4 (CC4) tended to increase in MCIc individuals compared to MCInc. Conclusions: The results suggest that A2M, FCN2, and FGG are promising biomarkers to discriminate AD patients from controls, which are worthy of further validation.
Background and Objective: Plasma biomarkers for Alzheimer’s disease (AD) diagnosis/stratification are intensively sought. However, there are no well-established plasma markers for AD diagnosis. Our group has identified and validated various blood-based proteomic biomarkers relating to AD pathology in multiple cohorts. The study aims to conduct a meta-analysis based on our own studies to systematically assess the diagnostic performance of our previously identified blood biomarkers. Methods: To do this, we included 7 studies that our group have conducted during the last decade. These studies used either Luminex xMAP or ELISA to measure proteomic biomarkers. As proteins measured in these studies differed, we selected protein based on the criteria that it must be measured in at least 4 studies. Biomarker performance was examined by random-effect meta-analyses based on the mean difference between biomarker concentrations in AD and controls (CTL), AD and mild cognitive impairment (MCI), MCI and CTL as well as MCI converted to dementia (MCIc) and non-converted (MCInc) individuals. Results: An overall of 2879 subjects were retrieved for meta-analysis including 1053 CTL, 895 MCI, 882 AD and 49 frontotemporal dementia (FTD) patients. Six proteins were measured in at least 4 studies and were chosen for meta-analyses for AD diagnosis. Of them, three proteins had significant difference between AD and controls, among which alpha-2-macroglobulin (A2M) and ficolin-2 (FCN2) increased in AD while fibrinogen gamma chain (FGG) decreased in AD compared to CTL. Furthermore, FGG significantly increased in FTD compared to AD. None of the proteins passed the significance between AD and MCI or MCI and CTL or MCIc and MCInc, although complement component 4 (CC4) tended to increase in MCIc individuals compared to MCInc. Conclusions: The results suggest that A2M, FCN2 and FGG are promising biomarkers to differentiate between AD patients and controls, which are worthy of further validation.
Author Nevado-Holgado, Alejo J.
Shi, Liu
Frisoni, Giovanni B.
Buckley, Noel J.
Engelborghs, Sebastiaan
Zetterberg, Henrik
Bertram, Lars
Sleegers, Kristel
Wallin, Anders
Legido-Quigley, Cristina
Bos, Isabelle
Lléo, Alberto
Visser, Pieter Jelle
Barkhof, Frederik
Popp, Julius
Martinez-Lage, Pablo
Lovestone, Simon
AuthorAffiliation 18 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , Mölndal , Sweden
21 Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck , Lübeck , Germany
6 Complex Genetics Group, VIB Center for Molecular Neurology, VIB , Antwerp , Belgium
9 Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg , Mölndal , Sweden
11 Department of Psychiatry, University Hospital of Lausanne , Lausanne , Switzerland
14 Kings College London , London , United Kingdom
19 UK Dementia Research Institute at UCL , London , United Kingdom
7 Institute Born-Bunge, Department of Biomedical Sciences, University of Antwerp , Antwerp , Belgium
15 The Systems Medicine Group, Steno Diabetes Center , Gentofte , Denmark
20 Department of Neurodegenerative Disease, UCL Institute of Neurology , London , United Kingdom
3 Alzheimer Center , VU University Medical Center, Amsterdam , Netherlands
8 Department of Psychi
AuthorAffiliation_xml – name: 18 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital , Mölndal , Sweden
– name: 3 Alzheimer Center , VU University Medical Center, Amsterdam , Netherlands
– name: 6 Complex Genetics Group, VIB Center for Molecular Neurology, VIB , Antwerp , Belgium
– name: 19 UK Dementia Research Institute at UCL , London , United Kingdom
– name: 20 Department of Neurodegenerative Disease, UCL Institute of Neurology , London , United Kingdom
– name: 21 Lübeck Interdisciplinary Platform for Genome Analytics, University of Lübeck , Lübeck , Germany
– name: 7 Institute Born-Bunge, Department of Biomedical Sciences, University of Antwerp , Antwerp , Belgium
– name: 10 Hospital de la Santa Creu i Sant Pau , Barcelona , Spain
– name: 11 Department of Psychiatry, University Hospital of Lausanne , Lausanne , Switzerland
– name: 22 Department of Psychology, University of Oslo , Oslo , Norway
– name: 8 Department of Psychiatry, University of Geneva , Geneva , Switzerland
– name: 13 CITA-Alzheimer Foundation , San Sebastian , Spain
– name: 14 Kings College London , London , United Kingdom
– name: 15 The Systems Medicine Group, Steno Diabetes Center , Gentofte , Denmark
– name: 2 Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centrum Limburg, Maastricht University , Maastricht , Netherlands
– name: 23 Janssen R&D , High Wycombe , United Kingdom
– name: 12 Geriatric Psychiatry, Department of Mental Health and Psychiatry, Geneva University Hospitals , Geneva , Switzerland
– name: 4 Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge, Department of Biomedical Sciences, University of Antwerp , Antwerp , Belgium
– name: 17 UCL Institutes of Neurology and Healthcare Engineering , London , United Kingdom
– name: 5 Department of Neurology, Universitair Ziekenhuis Brussel and Center for Neurociences (C4N), Vrije Universiteit Brussel , Brussels , Belgium
– name: 16 Department of Radiology and Nuclear Medicine, VU University Medical Center , Amsterdam , Netherlands
– name: 1 Department of Psychiatry, University of Oxford , Oxford , United Kingdom
– name: 9 Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg , Mölndal , Sweden
Author_xml – sequence: 1
  givenname: Liu
  surname: Shi
  fullname: Shi, Liu
– sequence: 2
  givenname: Noel J.
  surname: Buckley
  fullname: Buckley, Noel J.
– sequence: 3
  givenname: Isabelle
  surname: Bos
  fullname: Bos, Isabelle
– sequence: 4
  givenname: Sebastiaan
  surname: Engelborghs
  fullname: Engelborghs, Sebastiaan
– sequence: 5
  givenname: Kristel
  surname: Sleegers
  fullname: Sleegers, Kristel
– sequence: 6
  givenname: Giovanni B.
  surname: Frisoni
  fullname: Frisoni, Giovanni B.
– sequence: 7
  givenname: Anders
  surname: Wallin
  fullname: Wallin, Anders
– sequence: 8
  givenname: Alberto
  surname: Lléo
  fullname: Lléo, Alberto
– sequence: 9
  givenname: Julius
  surname: Popp
  fullname: Popp, Julius
– sequence: 10
  givenname: Pablo
  surname: Martinez-Lage
  fullname: Martinez-Lage, Pablo
– sequence: 11
  givenname: Cristina
  surname: Legido-Quigley
  fullname: Legido-Quigley, Cristina
– sequence: 12
  givenname: Frederik
  surname: Barkhof
  fullname: Barkhof, Frederik
– sequence: 13
  givenname: Henrik
  surname: Zetterberg
  fullname: Zetterberg, Henrik
– sequence: 14
  givenname: Pieter Jelle
  surname: Visser
  fullname: Visser, Pieter Jelle
– sequence: 15
  givenname: Lars
  surname: Bertram
  fullname: Bertram, Lars
– sequence: 16
  givenname: Simon
  surname: Lovestone
  fullname: Lovestone, Simon
– sequence: 17
  givenname: Alejo J.
  surname: Nevado-Holgado
  fullname: Nevado-Holgado, Alejo J.
BackLink https://gup.ub.gu.se/publication/307598$$DView record from Swedish Publication Index
BookMark eNp1kstu1DAYhSNURC_0AdhZYsMmg6-JwwJpWm6ViqbisrZs50_qIYkHO6FqV7wGr8eT4JkUiamEN7aOv3OsXz7H2cHgB8iyZwQvGJPVy2bQrVtQTMmiJFRw8Sg7IkXBcs4KcfDP-TA7jXGN02IMYyGfZIcs6YVk5Chrrzode42ugh_B986iM-d7Hb5BiOgTdHp0Q4tGj5bd3TW4HsLvn78ieuMi6Aiv0BJ9hFHny0F3t9FFdJbUGvkBraaAVjcD-jxOtYP4NHvc6C7C6f1-kn199_bL-Yf8cvX-4nx5mVuB5ZhT4CWpa1mALY0AYkCYkhssABdYGCDEcG0JF0ZoXEibBqGYyKbSpsFGEnaSXcy5tddrtQkuzXKrvHZqJ_jQKh1GZztQFKiVVWMwp5xzySvdNAUDBrSpWdnolJXPWfEGNpPZS2unjUpSO6kIiuFSVDLxr2c-wT3UFoYx6G7Ptn8zuGvV-h9KMiaELFPAi_uA4L9PEEfVu2ih6_QAfoqKClEVJas4TujzB-jaTyH9wo5iBeGY0kSVM2WDjzFAo6wb05f67fuuUwSrbZfUrktq2yU1dyk5yQPn3zH-7_kDgm7PWg
CitedBy_id crossref_primary_10_3390_ijms23147907
crossref_primary_10_1134_S0006297922080089
crossref_primary_10_3389_fragi_2023_1112109
crossref_primary_10_1038_s41398_024_02915_x
crossref_primary_10_3390_molecules27123947
crossref_primary_10_1021_acs_jproteome_3c00496
crossref_primary_10_47836_mjmhs_19_5_38
crossref_primary_10_1002_alz_13565
crossref_primary_10_1042_BST20210369
crossref_primary_10_2478_jtim_2022_0024
crossref_primary_10_1186_s13287_024_03820_2
crossref_primary_10_1016_j_drudis_2022_01_016
crossref_primary_10_3390_ijms25021231
Cites_doi 10.1001/archgenpsychiatry.2010.78
10.1093/brain/awaa286
10.3233/JAD-170531
10.1111/j.1526-4610.2011.01959.x
10.1007/s40120-017-0073-9
10.1016/S1474-4422(20)30071-5
10.3389/fneur.2015.00236
10.2967/jnumed.116.185017
10.1038/s41398-020-01137-1
10.1212/wnl.34.7.939
10.1523/JNEUROSCI.5626-11.2012
10.1111/j.1582-4934.2008.00434.x
10.1016/j.dadm.2014.11.005
10.1093/brain/awl279
10.1093/jmcb/mjs032
10.1007/s00592-015-0780-6
10.18637/jss.v036.i03
10.1186/s13041-019-0448-1
10.2174/1381612826666200114105515
10.1016/j.pneurobio.2012.06.007
10.1186/s13195-021-00804-9
10.1038/s41380-020-00923-z
10.2337/diabetes.53.2.474
10.1016/S1474-4422(09)70299-6
10.3233/JAD-190434
10.1016/j.neurobiolaging.2020.05.011
10.1084/jem.20200861
10.3233/JAD-2010-101350
10.1093/braincomms/fcab008
10.1073/pnas.1010373107
10.1172/JCI59903
10.1186/s13195-021-00805-8
10.1371/journal.pone.0003224
10.3233/JAD-200900
10.1007/s00702-018-01967-w
10.1371/journal.pone.0028527
10.3233/JAD-151155
10.1155/2012/138797
10.3389/fnagi.2018.00409
10.1016/j.jalz.2018.02.018
10.1016/j.jalz.2014.05.1749
10.1111/j.0105-2896.2004.0123.x
10.1016/j.jalz.2013.09.016
10.1038/nature25456
10.1038/s41591-020-0762-2
10.1186/s13195-017-0258-6
10.1097/NEN.0b013e31824b211b
10.1001/jamaneurol.2020.4201
10.1371/journal.pone.0044260
10.1016/s0531-5565(00)00113-3
10.1016/j.jalz.2011.03.005
ContentType Journal Article
Copyright 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright © 2021 Shi, Buckley, Bos, Engelborghs, Sleegers, Frisoni, Wallin, Lléo, Popp, Martinez-Lage, Legido-Quigley, Barkhof, Zetterberg, Visser, Bertram, Lovestone and Nevado-Holgado.
Copyright © 2021 Shi, Buckley, Bos, Engelborghs, Sleegers, Frisoni, Wallin, Lléo, Popp, Martinez-Lage, Legido-Quigley, Barkhof, Zetterberg, Visser, Bertram, Lovestone and Nevado-Holgado. 2021 Shi, Buckley, Bos, Engelborghs, Sleegers, Frisoni, Wallin, Lléo, Popp, Martinez-Lage, Legido-Quigley, Barkhof, Zetterberg, Visser, Bertram, Lovestone and Nevado-Holgado
Copyright_xml – notice: 2021. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright © 2021 Shi, Buckley, Bos, Engelborghs, Sleegers, Frisoni, Wallin, Lléo, Popp, Martinez-Lage, Legido-Quigley, Barkhof, Zetterberg, Visser, Bertram, Lovestone and Nevado-Holgado.
– notice: Copyright © 2021 Shi, Buckley, Bos, Engelborghs, Sleegers, Frisoni, Wallin, Lléo, Popp, Martinez-Lage, Legido-Quigley, Barkhof, Zetterberg, Visser, Bertram, Lovestone and Nevado-Holgado. 2021 Shi, Buckley, Bos, Engelborghs, Sleegers, Frisoni, Wallin, Lléo, Popp, Martinez-Lage, Legido-Quigley, Barkhof, Zetterberg, Visser, Bertram, Lovestone and Nevado-Holgado
DBID AAYXX
CITATION
3V.
7X7
7XB
88I
8FE
8FH
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
FYUFA
GHDGH
GNUQQ
HCIFZ
K9.
LK8
M0S
M2P
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
ADTPV
AOWAS
F1U
DOA
DOI 10.3389/fnagi.2021.712545
DatabaseName CrossRef
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Journals
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Central Student
SciTech Premium Collection
ProQuest Health & Medical Complete (Alumni)
Biological Sciences
Health & Medical Collection (Alumni)
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
SwePub
SwePub Articles
SWEPUB Göteborgs universitet
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
Biological Science Database
ProQuest SciTech Collection
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
CrossRef
MEDLINE - Academic

Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1663-4365
ExternalDocumentID oai_doaj_org_article_2e2c89fb042444849aff63e3e2fd37fa
oai_gup_ub_gu_se_307598
PMC8335587
10_3389_fnagi_2021_712545
GeographicLocations United States--US
San Francisco California
California
GeographicLocations_xml – name: San Francisco California
– name: United States--US
– name: California
GroupedDBID ---
53G
5VS
7X7
88I
8FE
8FH
8FI
8FJ
9T4
AAFWJ
AAYXX
ABIVO
ABUWG
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AEGXH
AENEX
AFKRA
AFPKN
AIAGR
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
BVXVI
CCPQU
CITATION
DIK
DWQXO
E3Z
EIHBH
F5P
FYUFA
GNUQQ
GROUPED_DOAJ
GX1
HCIFZ
HMCUK
HYE
KQ8
LK8
M2P
M48
M7P
M~E
O5R
O5S
OK1
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
TR2
UKHRP
3V.
7XB
8FK
K9.
PKEHL
PQEST
PQGLB
PQUKI
PRINS
Q9U
7X8
5PM
ADTPV
AOWAS
F1U
IPNFZ
RIG
PUEGO
ID FETCH-LOGICAL-c508t-2e471dd86ec7b5e1be5b74b05e0605be11b4ac145b5a068c3432018f9abf0b813
IEDL.DBID DOA
ISSN 1663-4365
IngestDate Wed Aug 27 01:23:29 EDT 2025
Thu Aug 21 07:30:11 EDT 2025
Thu Aug 21 18:09:35 EDT 2025
Fri Jul 11 10:59:41 EDT 2025
Fri Jul 25 11:53:44 EDT 2025
Tue Jul 01 04:03:37 EDT 2025
Thu Apr 24 23:03:34 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c508t-2e471dd86ec7b5e1be5b74b05e0605be11b4ac145b5a068c3432018f9abf0b813
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 14
ObjectType-Feature-3
ObjectType-Evidence Based Healthcare-1
ObjectType-Article-1
ObjectType-Feature-2
content type line 23
Edited by: Can Martin Zhang, Harvard Medical School, United States
Reviewed by: Jordi A. Matias-Guiu, Hospital Clínico San Carlos, Spain; David Morgan, Michigan State University, United States
OpenAccessLink https://doaj.org/article/2e2c89fb042444849aff63e3e2fd37fa
PMID 34366831
PQID 2553614022
PQPubID 4424411
ParticipantIDs doaj_primary_oai_doaj_org_article_2e2c89fb042444849aff63e3e2fd37fa
swepub_primary_oai_gup_ub_gu_se_307598
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8335587
proquest_miscellaneous_2559673940
proquest_journals_2553614022
crossref_citationtrail_10_3389_fnagi_2021_712545
crossref_primary_10_3389_fnagi_2021_712545
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2021-07-21
PublicationDateYYYYMMDD 2021-07-21
PublicationDate_xml – month: 07
  year: 2021
  text: 2021-07-21
  day: 21
PublicationDecade 2020
PublicationPlace Lausanne
PublicationPlace_xml – name: Lausanne
PublicationTitle Frontiers in aging neuroscience
PublicationYear 2021
Publisher Frontiers Research Foundation
Frontiers Media S.A
Publisher_xml – name: Frontiers Research Foundation
– name: Frontiers Media S.A
References Chen (B9) 2012; 4
Zetterberg (B50) 2019; 12
Koychev (B26) 2021; 79
Zhang (B51) 2016; 53
Beach (B6) 2012; 71
Kilpatrick (B23) 2012; 2012
de Almeida (B12) 2011; 51
Jack (B17) 2010; 9
Tosun (B44) 2021; 3
Shi (B37) 2018; 62
Ashton (B2) 2015; 1
Sattlecker (B35) 2014; 10
Klohs (B24) 2012; 32
Janelidze (B18) 2021; 78
Clark (B11) 2021; 13
Blennow (B7) 2017; 6
Nakamura (B33) 2018; 554
Thambisetty (B42); 22
Westwood (B47) 2020; 74
Barthélemy (B5) 2020; 217
Kovacs (B25) 2000; 35
Selvackadunco (B36) 2019; 126
Ryu (B34) 2009; 13
Mattsson-Carlgren (B30) 2020; 143
Li (B27) 2008; 3
Viechtbauer (B45) 2010; 36
Thambisetty (B40) 2011; 6
McKhann (B31) 2011; 7
Lista (B28) 2013
Westwood (B46) 2018; 10
Westwood (B49) 2016; 52
Kiddle (B22) 2012; 7
Westwood (B48) 2017; 9
Hye (B14) 2014; 10
Talbot (B39) 2012; 122
Ahn (B1) 2010; 107
Baird (B3) 2015; 6
Chatterjee (B8) 2021; 11
Sugarman (B38) 2020; 94
Cicognola (B10) 2021; 13
Fujita (B13) 2004; 198
Jack (B16) 2018; 14
Barthel (B4) 2017; 58
Manzine (B29) 2020; 26
Thambisetty (B41); 67
Karikari (B20) 2021; 26
Hye (B15) 2006; 129
Karikari (B21) 2020; 19
Janson (B19) 2004; 53
McKhann (B32) 1984; 34
Thijssen (B43) 2020; 26
References_xml – volume: 67
  start-page: 739
  ident: B41
  article-title: Association of plasma clusterin concentration with severity, pathology and progression in Alzheimer disease
  publication-title: Arch. Gen. Psychiatry
  doi: 10.1001/archgenpsychiatry.2010.78
– volume: 143
  start-page: 3234
  year: 2020
  ident: B30
  article-title: Longitudinal plasma p-tau217 is increased in early stages of Alzheimer’s disease
  publication-title: Brain
  doi: 10.1093/brain/awaa286
– volume: 62
  start-page: 1181
  year: 2018
  ident: B37
  article-title: A decade of blood biomarkers for Alzheimer’s disease research: an evolving field, improving study designs and the challenge of replication
  publication-title: J. Alzheimers Dis.
  doi: 10.3233/JAD-170531
– volume: 51
  start-page: 1503
  year: 2011
  ident: B12
  article-title: Incidence of post-dural puncture headache in research volunteers
  publication-title: Headache
  doi: 10.1111/j.1526-4610.2011.01959.x
– volume: 6
  start-page: 15
  year: 2017
  ident: B7
  article-title: A review of fluid biomarkers for Alzheimer’s disease: moving from CSF to blood
  publication-title: Neurol. Ther.
  doi: 10.1007/s40120-017-0073-9
– volume: 19
  start-page: 422
  year: 2020
  ident: B21
  article-title: Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(20)30071-5
– volume: 6
  start-page: 236
  year: 2015
  ident: B3
  article-title: Blood-based proteomic biomarkers of Alzheimer’s disease pathology
  publication-title: Front. Neurol.
  doi: 10.3389/fneur.2015.00236
– volume: 58
  start-page: 1711
  year: 2017
  ident: B4
  article-title: Clinical use and utility of amyloid imaging
  publication-title: J. Nucl. Med.
  doi: 10.2967/jnumed.116.185017
– volume: 11
  start-page: 27
  year: 2021
  ident: B8
  article-title: Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer’s disease
  publication-title: Transl. Psychiatry
  doi: 10.1038/s41398-020-01137-1
– volume: 34
  start-page: 939
  year: 1984
  ident: B32
  article-title: Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease
  publication-title: Neurology
  doi: 10.1212/wnl.34.7.939
– volume: 32
  start-page: 1705
  year: 2012
  ident: B24
  article-title: Contrast-enhanced magnetic resonance microangiography reveals remodeling of the cerebral microvasculature in transgenic ArcAβ mice
  publication-title: J. Neurosci.
  doi: 10.1523/JNEUROSCI.5626-11.2012
– volume: 13
  start-page: 2911
  year: 2009
  ident: B34
  article-title: A leaky blood-brain barrier, fibrinogen infiltration and microglial reactivity in inflamed Alzheimer’s disease brain
  publication-title: J. Cell. Mol. Med.
  doi: 10.1111/j.1582-4934.2008.00434.x
– volume: 1
  start-page: 48
  year: 2015
  ident: B2
  article-title: Blood protein predictors of brain amyloid for enrichment in clinical trials?
  publication-title: Alzheimers Dement.
  doi: 10.1016/j.dadm.2014.11.005
– volume: 129
  start-page: 3042
  year: 2006
  ident: B15
  article-title: Proteome-based plasma biomarkers for Alzheimer’s disease
  publication-title: Brain
  doi: 10.1093/brain/awl279
– volume: 4
  start-page: 256
  year: 2012
  ident: B9
  article-title: Low serum levels of the innate immune component ficolin-3 is associated with insulin resistance and predicts the development of type 2 diabetes
  publication-title: J. Mol. Cell Biol.
  doi: 10.1093/jmcb/mjs032
– volume: 53
  start-page: 295
  year: 2016
  ident: B51
  article-title: Low levels of ficolin-3 are associated with diabetic peripheral neuropathy
  publication-title: Acta Diabetol.
  doi: 10.1007/s00592-015-0780-6
– volume: 36
  start-page: 1
  year: 2010
  ident: B45
  article-title: Conducting meta-analyses in R with the metafor package
  publication-title: J. Stat. Soft.
  doi: 10.18637/jss.v036.i03
– volume: 12
  start-page: 26
  year: 2019
  ident: B50
  article-title: Blood-based molecular biomarkers for Alzheimer’s disease
  publication-title: Mol. Brain
  doi: 10.1186/s13041-019-0448-1
– volume: 26
  start-page: 1300
  year: 2020
  ident: B29
  article-title: Blood-based biomarkers of Alzheimer’s disease: the long and winding road
  publication-title: Curr. Pharm. Des.
  doi: 10.2174/1381612826666200114105515
– start-page: 1
  year: 2013
  ident: B28
  article-title: Blood and plasma-based proteomic biomarker research in Alzheimer’s disease
  publication-title: Prog. Neurobiol.
  doi: 10.1016/j.pneurobio.2012.06.007
– volume: 13
  start-page: 68
  year: 2021
  ident: B10
  article-title: Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
  publication-title: Alzheimers Res. Ther.
  doi: 10.1186/s13195-021-00804-9
– volume: 26
  start-page: 429
  year: 2021
  ident: B20
  article-title: Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer’s Disease Neuroimaging Initiative
  publication-title: Mol. Psychiatry
  doi: 10.1038/s41380-020-00923-z
– volume: 53
  start-page: 474
  year: 2004
  ident: B19
  article-title: Increased risk of type 2 diabetes in Alzheimer disease
  publication-title: Diabetes
  doi: 10.2337/diabetes.53.2.474
– volume: 9
  start-page: 119
  year: 2010
  ident: B17
  article-title: Hypothetical model of dynamic biomarkers of the Alzheimer’s pathological cascade
  publication-title: Lancet Neurol.
  doi: 10.1016/S1474-4422(09)70299-6
– volume: 74
  start-page: 213
  year: 2020
  ident: B47
  article-title: Validation of plasma proteomic biomarkers relating to brain amyloid burden in the EMIF-Alzheimer’s disease multimodal biomarker discovery cohort
  publication-title: J. Alzheimers Dis.
  doi: 10.3233/JAD-190434
– volume: 94
  start-page: 60
  year: 2020
  ident: B38
  article-title: A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer’s disease
  publication-title: Neurobiol. Aging
  doi: 10.1016/j.neurobiolaging.2020.05.011
– volume: 217
  start-page: e20200861
  year: 2020
  ident: B5
  article-title: Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer’s disease
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20200861
– volume: 22
  start-page: 1099
  ident: B42
  article-title: Proteome-based plasma markers of brain amyloid-beta deposition in non-demented older individuals
  publication-title: J. Alzheimers Dis.
  doi: 10.3233/JAD-2010-101350
– volume: 3
  start-page: fcab008
  year: 2021
  ident: B44
  article-title: Detection of β-amyloid positivity in Alzheimer’s Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers
  publication-title: Brain Commun.
  doi: 10.1093/braincomms/fcab008
– volume: 107
  start-page: 21812
  year: 2010
  ident: B1
  article-title: Alzheimer’s disease peptide beta-amyloid interacts with fibrinogen and induces its oligomerization
  publication-title: Proc. Natl. Acad. Sci. U S A
  doi: 10.1073/pnas.1010373107
– volume: 122
  start-page: 1316
  year: 2012
  ident: B39
  article-title: Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation and cognitive decline
  publication-title: J. Clin. Invest.
  doi: 10.1172/JCI59903
– volume: 13
  start-page: 65
  year: 2021
  ident: B11
  article-title: Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
  publication-title: Alzheimers Res. Ther.
  doi: 10.1186/s13195-021-00805-8
– volume: 3
  start-page: e3224
  year: 2008
  ident: B27
  article-title: Localized-statistical quantification of human serum proteome associated with type 2 diabetes
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0003224
– volume: 79
  start-page: 177
  year: 2021
  ident: B26
  article-title: Blood-based ATN biomarkers of Alzheimer’s disease: a meta-analysis
  publication-title: J. Alzheimers Dis.
  doi: 10.3233/JAD-200900
– volume: 126
  start-page: 327
  year: 2019
  ident: B36
  article-title: Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the brains for dementia research (BDR) cohort
  publication-title: J. Neural Transm.
  doi: 10.1007/s00702-018-01967-w
– volume: 6
  start-page: e28527
  year: 2011
  ident: B40
  article-title: Plasma biomarkers of brain atrophy in Alzheimer’s disease
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0028527
– volume: 52
  start-page: 561
  year: 2016
  ident: B49
  article-title: Blood-based biomarker candidates of cerebral amyloid using PiB PET in non-demented elderly
  publication-title: J. Alzheimers Dis.
  doi: 10.3233/JAD-151155
– volume: 2012
  start-page: 138797
  year: 2012
  ident: B23
  article-title: Human L-ficolin (ficolin-2) and its clinical significance
  publication-title: J. Biomed. Biotechnol.
  doi: 10.1155/2012/138797
– volume: 10
  start-page: 409
  year: 2018
  ident: B46
  article-title: Plasma protein biomarkers for the prediction of csf amyloid and tau and [18F]-flutemetamol PET scan result
  publication-title: Front. Aging Neurosci.
  doi: 10.3389/fnagi.2018.00409
– volume: 14
  start-page: 535
  year: 2018
  ident: B16
  article-title: NIA-AA research framework: toward a biological definition of Alzheimer’s disease
  publication-title: Alzheimers Dement.
  doi: 10.1016/j.jalz.2018.02.018
– volume: 10
  start-page: 799.e2
  year: 2014
  ident: B14
  article-title: Plasma proteins predict conversion to dementia from prodromal disease
  publication-title: Alzheimers Dement.
  doi: 10.1016/j.jalz.2014.05.1749
– volume: 198
  start-page: 185
  year: 2004
  ident: B13
  article-title: The lectin-complement pathway–its role in innate immunity and evolution
  publication-title: Immunol. Rev.
  doi: 10.1111/j.0105-2896.2004.0123.x
– volume: 10
  start-page: 724
  year: 2014
  ident: B35
  article-title: Alzheimer’s disease biomarker discovery using SOMAscan multiplexed protein technology
  publication-title: Alzheimers Dement.
  doi: 10.1016/j.jalz.2013.09.016
– volume: 554
  start-page: 249
  year: 2018
  ident: B33
  article-title: High performance plasma amyloid-β biomarkers for Alzheimer’s disease
  publication-title: Nature
  doi: 10.1038/nature25456
– volume: 26
  start-page: 387
  year: 2020
  ident: B43
  article-title: Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-0762-2
– volume: 9
  start-page: 31
  year: 2017
  ident: B48
  article-title: The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer’s pathology
  publication-title: Alzheimers Res. Ther.
  doi: 10.1186/s13195-017-0258-6
– volume: 71
  start-page: 266
  year: 2012
  ident: B6
  article-title: Accuracy of the clinical diagnosis of Alzheimer disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010
  publication-title: J. Neuropathol. Exp. Neurol.
  doi: 10.1097/NEN.0b013e31824b211b
– volume: 78
  start-page: 149
  year: 2021
  ident: B18
  article-title: Associations of plasma phospho-Tau217 levels with tau positron emission tomography in early Alzheimer disease
  publication-title: JAMA Neurol.
  doi: 10.1001/jamaneurol.2020.4201
– volume: 7
  start-page: e44260
  year: 2012
  ident: B22
  article-title: Plasma based markers of [11C] PiB-PET brain amyloid burden
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0044260
– volume: 35
  start-page: 473
  year: 2000
  ident: B25
  article-title: alpha2-macroglobulin in late-onset Alzheimer’s disease
  publication-title: Exp. Gerontol.
  doi: 10.1016/s0531-5565(00)00113-3
– volume: 7
  start-page: 263
  year: 2011
  ident: B31
  article-title: The diagnosis of dementia due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s association workgroups on diagnostic guidelines for Alzheimer’s disease
  publication-title: Alzheimers Dement.
  doi: 10.1016/j.jalz.2011.03.005
SSID ssj0000330058
Score 2.3428123
Snippet Background and Objective : Plasma biomarkers for the diagnosis and stratification of Alzheimer’s disease (AD) are intensively sought. However, no plasma...
Background and Objective: Plasma biomarkers for Alzheimer’s disease (AD) diagnosis/stratification are intensively sought. However, there are no...
Background and Objective: Plasma biomarkers for the diagnosis and stratification of Alzheimer's disease (AD) are intensively sought. However, no plasma markers...
Background and Objective: Plasma biomarkers for the diagnosis and stratification of Alzheimer’s disease (AD) are intensively sought. However, no plasma markers...
SourceID doaj
swepub
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Enrichment Source
Index Database
StartPage 712545
SubjectTerms Aging
Alzheimer's disease
Alzheimer's disease (AD)
Apolipoproteins
association
Biomarkers
blood
blood biomarkers
clinical-diagnosis
Cognitive ability
Cytotoxicity
Dementia
Dementia disorders
Diagnosis
Fibrinogen
Frontotemporal dementia
Geriatrics & Gerontology
insulin-resistance
Lifestyles
Lymphocytes T
Meta-analysis
national institute
Neurodegenerative diseases
neurofilament light
Neuroscience
Neurosciences
Neurosciences & Neurology
Neurovetenskaper
Pathology
phosphorylated tau 181
Plasma
Proteins
proteomic
α2-Macroglobulin
SummonAdditionalLinks – databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Ni9QwFA-6gngRP7G6SgTxIMRt2qZpvciMuizCuHtwYW4hSdPuwE47dloW9uS_4b_nX-J7bWa0HvaaDwh5eXnfv0fIG1QyhJYlc1pkLOGFZMblBTM8B27KjUw1-iEX39KT8-TrUiy9w23r0yp3f-LwUReNRR_5Eai-MYgSEDkfNz8Ydo3C6KpvoXGb3EHoMkzpkku597GEMYKxD9VwIFhZEqdiDGyCXZYfldgHCCzEiL-XIOaxoOkf0TQg-E_Uzv-TJifQooM4On5A7ns9ks5Gwj8kt1z9iNxd-Ej5Y1KdgVq81vQMcRiw8pjOV80ac3HaLR0z4OqKdg2dXV5fuNXatb9__trSz2O85gOd0YXrNNthltA5jBa0qelp39LTq5r6BMQn5Pz4y_dPJ8w3VWAWdLGORQ7EUVFkqbPSCMeNE0YmJhQuBMvGOM5Noi1PhBE6TDOLhachz8pcmzI0GY-fkoO6qd0zQq0JdaRNDBqnTcAwNJKX2PcXTBge2jwMSLi7T2U94jg2vrhUYHkgCdRAAoUkUCMJAvJuv2Uzwm3ctHiORNovRKTsYaBpK-UZT0UuslleGgzxgima5Los09jFLiqLWJY6IIc7EivPvlv197EF5PV-GhgPoym6dk0_rMlTiY3lAyInT2NyoOlMvboYILyx1E1kMiBvx0c02VL1GwVDVa-2TsEfLPLs-c2nfEHu4b2gzznih-Sga3v3EpSlzrwaOOIPOWQUtg
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1di9QwFA3rCuKL-InVVSKID0LXpm2aVhCZUZdFGHcfHNi3kKRJd2CmXTstu_rk3_Dv-Uu8tx8DlcUnX9ME2tzc3HN6k3MJeYkggyvhfKt46scsF762We5rloE3ZVokCv9DLr4kx8v48xk_2yNjeathArfXUjusJ7Ws14dX376_B4d_h4wT4u0bhwV9gOqF7FBAvI75DXITApNAP10MaL_bmCPUZk_73Ob1IyfRqRPxnyDPv89NTtRFu4h0dJfcGaAknfW2v0f2bHmf3FoMyfIHpDgFZLxR9BSlGPDyMZ2vqg0ex6m3tD8EVxa0qehs_ePcrja2_v3z15Z-7FM2b-mMLmyj_FG2hM6hNadVSU_amp5clnQ4g_iQLI8-ff1w7A91FXwDcKzxQwsRKc_TxBqhuWXaci1iHXAbALnRljEdK8NirrkKktTg3dOApS5T2gU6ZdEjsl9WpX1MqNGBCpWOAHSaGLihFsxh6V9gMSwwWeCRYJxPaQbRcax9sZZAPtAEsjOBRBPI3gQeeb0bctErbvyr8xyNtOuIYtldQ1UXcvA9GdrQpJnTmOUFNhpnyrkkspENXR4JpzxyMJpYjgtQAtWKALoAxPHIi91j8D1MqKjSVm3XJ0sE1pb3iJgsjckLTZ-Uq_NOxRtvu_FUeORVv4gmQ4r2QkJT0cqtlbAN8yx98j8-9Sm5jbOHP6dDdkD2m7q1zwBVNfp55yt_AGE-I_w
  priority: 102
  providerName: Scholars Portal
Title Plasma Proteomic Biomarkers Relating to Alzheimer’s Disease: A Meta-Analysis Based on Our Own Studies
URI https://www.proquest.com/docview/2553614022
https://www.proquest.com/docview/2559673940
https://pubmed.ncbi.nlm.nih.gov/PMC8335587
https://gup.ub.gu.se/publication/307598
https://doaj.org/article/2e2c89fb042444849aff63e3e2fd37fa
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NjtMwELZgkRAXxK8ILJWREAeksHESxza3FnZZIXW3QqzUm2UndrfSNlm1iZD2tK_B6_EkzCRp1XCAC5ccHFtKPGPPN57xN4S8RZDBjfChM1yGKStEaJ0qQssUrCZlRWbwHHJ6lp1epF_nfL5X6gtzwjp64G7ijmIX51J5iyE6cCVSZbzPEpe42BeJ8C00Apu350y1e3CCNOyyC2OCF6aOPFb9AX8wZh8EGHW8vrRniFq-_gHI_DNFckAk2hqfk0fkYY8a6bj72sfkjiufkPvTPi7-lCxmAIJXhs6QdQHvGdPJslph5s16Q7t8t3JB64qOr24u3XLl1r9uf27o5y4685GO6dTVJtwylNAJtBa0Kul5s6bnP0rapxs-Ixcnx98_nYZ9CYUwB-RVh7ED41MUMnO5sNwx67gVqY24i8CPsY4xm5qcpdxyE2Uyx2umEZNeGesjK1nynByUVeleEJrbyMTGJoAv8xTcQCuYxyq_4LCwKFdRQKLtfOq85xfHMhdXGvwMFIFuRaBRBLoTQUDe74Zcd-Qaf-s8QSHtOiIvdtsA2qJ7bdH_0paAHG5FrPvFutHgVSWAUgDNBOTN7jUsM4ydmNJVTdtHZQLLyAdEDFRj8EHDN-XysiXsxottXIqAvOuUaDBk0VxraFo0euM07LhcyZf_41dfkQc4e3gOHbNDclCvG_caAFRtR-SumIsRuTc5Ppt9G7UrB55f5gye01T-BuIIIEU
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9NAFH4qqQRcEKswFBgk4IBk6vE2NhJCCW2V0iaNUCv1Np2xx2mkxg5ZVMGJv8Gf4EfxS3jPS8Aceut1PLasedv35m0ArwhkBEpktlFBZPs8FbY2cWprHqM0xVqEiu4hB8Owf-J_Pg1ON-BXUwtDaZWNTiwVdVokdEe-jdDXQ1OCJufj7KtNU6MoutqM0KjY4sB8u0SXbfFhfwfp-9p193aPP_XteqqAnSAYWdquQX2cplFoEqEDw7UJtPC1ExgHob02nGtfJdwPdKCcMEqo8tLhURYrnTk64h5-9wZs-h66Mh3Y7O0OR1_WtzqOR-3fy_o7NOU2bgqqUCp6gvF2RpOH0Cd1-TuBwIJKqP4xhuXMgBbQ_T9Ns9XMtDSAe3fhTo1cWbditXuwYfL7cHNQx-YfwHiEQHyq2Ig6P1CtM-tNiill_8wXrMq5y8dsWbDuxfdzM5ma-e8fPxdsp4oQvWddNjBLZTddUlgPV1NW5OxoNWdHlzmrUx4fwsm1HPgj6ORFbh4DS7SjXKU9xLiJj66oFjyjScPoNHEniR0LnOY8ZVL3OKdRGxcSfR0igSxJIIkEsiKBBW_Xr8yqBh9Xbe4RkdYbqTd3uVDMx7IWdekaN4niTFNQGZ1fP1ZZFnrGM26WeiJTFmw1JJa1wljIv-xtwcv1YxR1it-o3BSrck8cChplb4FosUbrh9pP8sl52TSciuuCSFjwpmKi1ivj1Uzi0nglF0ai1g_i6MnVf_kCbvWPB4fycH948BRu0xnRjbfLt6CznK_MM4RqS_28lg8GZ9ctkn8A_NBS2Q
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3LbtQwFLVKkSo2iKcIFDASsEAKEydxnCAhNMMwainTzoJKszN2YqcjdZJhHqpgxW_wK3wOX8K9eQyERXfdOk4U-b7O9X0R8hxBBlfCukbx2A1ZJlxtkszVLAFpSrSIFN5Djo-jg9Pw45RPd8ivthYG0ypbnVgp6qxM8Y68B9A3AFMCJqdnm7SIyXD0bvHVxQlSGGltx2nULHJkvl2A-7Z6ezgEWr_w_dGHz-8P3GbCgJsCMFm7vgHdnGVxZFKhuWHacC1C7XHjAczXhjEdqpSFXHPlRXGKVZgei22itPV0zAL47jVyXQScoYyJqdje73gBNoKvKvHAqLthEPE6qAo-YdKzOIMIvFOfvRYAMbCY6h-zWE0P6EDe_xM2O21NK1M4ukVuNhiW9mumu012THGH7I2bKP1dkk8Aks8VnWAPCKx6poNZOcc8oOWK1tl3RU7XJe2ffz8zs7lZ_v7xc0WHdazoDe3TsVkrt-2XQgewmtGyoCebJT25KGiT_HiPnF7Jcd8nu0VZmAeEptpTvtIBoN00BKdUC2Zx5jC4T8xLE88hXnueMm26nePQjXMJXg-SQFYkkEgCWZPAIa-2ryzqVh-XbR4gkbYbsUt3tVAuc9kIvfSNn8aJ1RheBjc4TJS1UWAC49ssEFY5ZL8lsWxUx0r-ZXSHPNs-BqHHSI4qTLmp9iSRwKH2DhEd1uj8UPdJMTur2odjmR2PhUNe1kzUeSXfLCQs5Ru5MhL0P0_ih5f_5VOyB4IoPx0eHz0iN_CI8OrbZ_tkd73cmMeA2db6SSUclHy5amn8A-yYVak
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Plasma+Proteomic+Biomarkers+Relating+to+Alzheimer%E2%80%99s+Disease%3A+A+Meta-Analysis+Based+on+Our+Own+Studies&rft.jtitle=Frontiers+in+aging+neuroscience&rft.au=Liu+Shi&rft.au=Noel+J.+Buckley&rft.au=Isabelle+Bos&rft.au=Isabelle+Bos&rft.date=2021-07-21&rft.pub=Frontiers+Media+S.A&rft.eissn=1663-4365&rft.volume=13&rft_id=info:doi/10.3389%2Ffnagi.2021.712545&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_2e2c89fb042444849aff63e3e2fd37fa
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-4365&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-4365&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-4365&client=summon